Frailty and COVID-19 mRNA Vaccine Antibody Response in The COVID-19 Community Research Partnership.

MedStar author(s):
Citation: Journals of Gerontology Series A-Biological Sciences & Medical Sciences. 2022 Apr 21PMID: 35446945Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2022ISSN:
  • 1079-5006
Name of journal: The journals of gerontology. Series A, Biological sciences and medical sciencesAbstract: BACKGROUND: COVID-19 has disproportionately affected older adults. Frailty has been associated with impaired vaccine response in other vaccine types, but the impact of frailty on mRNA vaccine response is undefined.CONCLUSIONS: Overall antibody response to COVID-19 mRNA vaccination was high across age and frailty categories. While antibody detection is an incomplete descriptor of vaccine response, the high sensitivity of this antibody combined with health system data reinforce our conclusions that frailty is an independent predictor of impaired antibody response to the COVID-19 mRNA vaccines. Frailty should be considered in vaccine studies and prevention strategies. Copyright © The Author(s) 2022. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: [email protected]: Observational study of adults aged 55 and above from one US health care system between January 22, 2021 and September 16, 2021 with self-reported Moderna or Pfizer COVID-19 mRNA vaccine and an electronic frailty index score (eFI) from their medical record (n =1677). Participants ' frailty status was compared with positive antibody detection (seroconversion) following full vaccination and subsequent loss of positive antibody detection (seroreversion) using logistic regression models.RESULTS: Of 1677 older adults with median (IQR) age, 67 (62, 72) years, and frailty status (non-frail: 879 (52%), pre-frail: 678 (40%), and frail: 120 (7.2%)), seroconversion was not detected in 23 (1.4%) over 60 days following full vaccination. Frail individuals were less likely to seroconvert than non-frail individuals, adjusted OR 3.75, 95%CI (1.04, 13.5). Seroreversion was detected in 50/1631 individuals (3.1%) over 6 months of median follow up antibody testing. Frail individuals were more likely to serorevert than non-frail individuals, adjusted OR 3.02, 95%CI (1.17, 7.33).All authors: Alexander-Miller MA, Callahan KE, COVID-19 Community Research Partnership, DeWitt ME, Gibbs MA, Herrington DM, McCurdy LH, Munawar I, Sanders JW, Semelka CT, Weintraub WS, Yukich JOFiscal year: FY2022Digital Object Identifier: Date added to catalog: 2022-05-11
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 35446945 Available 35446945

BACKGROUND: COVID-19 has disproportionately affected older adults. Frailty has been associated with impaired vaccine response in other vaccine types, but the impact of frailty on mRNA vaccine response is undefined.

CONCLUSIONS: Overall antibody response to COVID-19 mRNA vaccination was high across age and frailty categories. While antibody detection is an incomplete descriptor of vaccine response, the high sensitivity of this antibody combined with health system data reinforce our conclusions that frailty is an independent predictor of impaired antibody response to the COVID-19 mRNA vaccines. Frailty should be considered in vaccine studies and prevention strategies. Copyright © The Author(s) 2022. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: [email protected].

METHODS: Observational study of adults aged 55 and above from one US health care system between January 22, 2021 and September 16, 2021 with self-reported Moderna or Pfizer COVID-19 mRNA vaccine and an electronic frailty index score (eFI) from their medical record (n =1677). Participants ' frailty status was compared with positive antibody detection (seroconversion) following full vaccination and subsequent loss of positive antibody detection (seroreversion) using logistic regression models.

RESULTS: Of 1677 older adults with median (IQR) age, 67 (62, 72) years, and frailty status (non-frail: 879 (52%), pre-frail: 678 (40%), and frail: 120 (7.2%)), seroconversion was not detected in 23 (1.4%) over 60 days following full vaccination. Frail individuals were less likely to seroconvert than non-frail individuals, adjusted OR 3.75, 95%CI (1.04, 13.5). Seroreversion was detected in 50/1631 individuals (3.1%) over 6 months of median follow up antibody testing. Frail individuals were more likely to serorevert than non-frail individuals, adjusted OR 3.02, 95%CI (1.17, 7.33).

English

Powered by Koha